E W Ades|C M Balch - JoVE Visualize

Showing results (111-120 of 232) with videos related to

Pageof 24

Sort By:

Annals of Surgery|November 1, 1983

A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pumpC M Balch, M M Urist, S J Soong, et al.

Melanoma Research|December 3, 1998

Is the capacity for lymph node-mediated distant dissemination the same for all nodal groups in malignant melanoma?C P Karakousis, C M Balch, A Bartolucci, et al.

Journal of Reproductive Immunology|December 1, 1980

Anti-ovarian and anti-lymphocyte antibodies in patients with chronic vaginal candidiasisS Mathur, J T Melchers, E W Ades, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1989

Altered biodistribution of indium-111-labeled monoclonal antibody 96.5 to tumors and normal tissues of nude mice bearing human melanoma xenografts in visceral organsD R McCready, J Price, C M Balch, et al.

American Journal of Clinical Pathology|June 1, 1981

Polypoid melanoma, a virulent variant of the nodular growth patternE A Manci, C M Balch, T M Murad, et al.

Surgery|January 1, 1984

Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patientsC M Balch, P A Dougherty, G A Cloud, et al.

Experimental Cell Biology|January 1, 1984

Immune response against vaccinia virus in rhesus monkeys: no evidence for primary MHC-restricted cytolytic T cellsL Stitz, R Zinkernagel, C M Balch, et al.

Annals of Surgery|August 1, 1983

Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patientsC M Balch, A B Tilden, P A Dougherty, et al.

Natural Immunity and Cell Growth Regulation|January 1, 1987

Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activityE W Ades, C R McKemie, S Wright, et al.

Journal of Clinical & Laboratory Immunology|October 1, 1987

An immunochemotherapy protocol for enhanced tumoricidal activity: in vivo treatment with IL-2 prior to chemotherapyW L Lockhart, C R McKemie, S Wright, et al.

Pageof 24

Showing results (111-120 of 232) with videos related to

Sort By:

Pageof 24

Annals of Surgery|November 1, 1983

A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pumpC M Balch, M M Urist, S J Soong, et al.

Melanoma Research|December 3, 1998

Is the capacity for lymph node-mediated distant dissemination the same for all nodal groups in malignant melanoma?C P Karakousis, C M Balch, A Bartolucci, et al.

Journal of Reproductive Immunology|December 1, 1980

Anti-ovarian and anti-lymphocyte antibodies in patients with chronic vaginal candidiasisS Mathur, J T Melchers, E W Ades, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1989

Altered biodistribution of indium-111-labeled monoclonal antibody 96.5 to tumors and normal tissues of nude mice bearing human melanoma xenografts in visceral organsD R McCready, J Price, C M Balch, et al.

American Journal of Clinical Pathology|June 1, 1981

Polypoid melanoma, a virulent variant of the nodular growth patternE A Manci, C M Balch, T M Murad, et al.

Surgery|January 1, 1984

Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patientsC M Balch, P A Dougherty, G A Cloud, et al.

Experimental Cell Biology|January 1, 1984

Immune response against vaccinia virus in rhesus monkeys: no evidence for primary MHC-restricted cytolytic T cellsL Stitz, R Zinkernagel, C M Balch, et al.

Annals of Surgery|August 1, 1983

Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patientsC M Balch, A B Tilden, P A Dougherty, et al.

Natural Immunity and Cell Growth Regulation|January 1, 1987

Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activityE W Ades, C R McKemie, S Wright, et al.

Journal of Clinical & Laboratory Immunology|October 1, 1987

An immunochemotherapy protocol for enhanced tumoricidal activity: in vivo treatment with IL-2 prior to chemotherapyW L Lockhart, C R McKemie, S Wright, et al.

Pageof 24